Annals of Surgical Oncology

, Volume 23, Issue 6, pp 1986–1992 | Cite as

Effect of EGFR and p-AKT Overexpression on Chromosomal Instability in Gastric Cancer

  • Yuichi Hisamatsu
  • Eiji Oki
  • Hajime Otsu
  • Koji Ando
  • Hiroshi Saeki
  • Eriko Tokunaga
  • Shinichi Aishima
  • Masaru Morita
  • Yoshinao Oda
  • Yoshihiko Maehara
Gastrointestinal Oncology



Molecular profiling in gastric cancer (GC) is important for diagnosis and treatment. In this study, we investigated signal transduction pathways that might induce chromosomal instability in GC.


Epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and p-AKT expression were analyzed using immunohistochemistry, and chromosomal instability was assessed by DNA aneuploidy using laser scanning cytometry, in a total of 202 GC cases.


The rate of EGFR expression and p-AKT expression was 70.3 and 34.2 %, respectively, in GC patients. In total, 57.5 % of GC patients exhibited DNA aneuploidy, and p-AKT positively correlated with EGFR and HER2 (p = 0.0127 and p = 0.00031, respectively). Patients with EGFR overexpressing GC showed shorter disease-specific survival than the other cases (hazard ratio 2.00, 95 % confidence interval 1.19–3.53; p = 0.0104). Moreover, EGFR and p-AKT expression was significantly correlated with DNA aneuploidy (p = 0.0002 and p = 0.0302, respectively).


Our data showed that both EGFR and p-AKT overexpression were clearly associated with DNA aneuploidy. Aneuploidy could be a useful marker for therapies that target EGFR.


Gastric Cancer Epidermal Growth Factor Receptor Gastric Cancer Patient Gastric Cancer Cell Line Epidermal Growth Factor Receptor Expression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors thank Ms. Y. Kubota for her wonderful work in preparing the IHC samples, and Ms. T. Shishino and Ms. N. Makikusa for their technical assistance.


Yuichi Hisamatsu, Eiji Oki, Hajime Otsu, Koji Ando, Hiroshi Saeki, Eriko Tokunaga, Shinichi Aishima, Masaru Morita, Yoshinao Oda, and Yoshihiko Maehara had no financial or personal relationships with other people or organizations that could inappropriately influence this work.

Supplementary material

10434_2016_5097_MOESM1_ESM.docx (28 kb)
Supplementary material 1 (DOCX 28 kb).
10434_2016_5097_MOESM2_ESM.tif (890 kb)
Supplementary material 2 Figure 1. Immunohistochemical analysis of EGFR and p-AKT in normal gastric tissue. Representative images showing EGFR expression in gastric normal specimens (A, B). Cells were considered EGFR (A) or EGFR+ (B) according to positive immunostaining of the cell membrane. Original magnification: ×200. (TIFF 891 kb).
10434_2016_5097_MOESM3_ESM.tif (26 kb)
Supplementary material 3 Supplementary Figure 2. The level of EGFR expression in NCI-N87 cells. Western blotting analysis using anti-EGFR (sc-03) rabbit polyclonal antibody indicated a band at the predicted size (170 kDa) (TIFF 26 kb).


  1. 1.
    Yasui W, Sentani K, Sakamoto N, Anami K, Naito Y, Oue N. Molecular Pathology of Gastric Cancer: Research and Practice. Pathol Res Pract. 2011; 207:608–12.CrossRefPubMedGoogle Scholar
  2. 2.
    Cervantes A, Roselló S, Roda D, Rodríguez-Braun E. The treatment of advanced gastric cancer: current strategies and future perspectives. Ann Oncol. 2008;19:103–07.CrossRefGoogle Scholar
  3. 3.
    Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–9.CrossRefGoogle Scholar
  4. 4.
    Wang K, Yuen ST, Xu J, et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet. 2014;46:573–82CrossRefPubMedGoogle Scholar
  5. 5.
    Mertens F, Johansson B, Mitelman F. Isochromosomes in neoplasia. Genes Chro- mosomes Cancer. 1994;10:221–30.CrossRefPubMedGoogle Scholar
  6. 6.
    Nam H-J, Chae S, Jang S-H, Cho H, Lee J-H. Carcinogenesis. 2010;31:1531–40CrossRefPubMedGoogle Scholar
  7. 7.
    Bang YJ. Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer. J Clin Gastroenterol. 2012;46:637–48CrossRefPubMedGoogle Scholar
  8. 8.
    Ye D, Mendelsohn J, Fan Z. Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Oncogene. 1999; 18:731–38.CrossRefPubMedGoogle Scholar
  9. 9.
    Schlessinger J. Common and distinct elements in cellular signaling via EGF and FGF receptors. Science. 2004; 306:1506–07.CrossRefPubMedGoogle Scholar
  10. 10.
    Kim JS, Kim MA, Kim TM, et al. Biomarker analysis in stage III–IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favorable survival. Br J Cancer. 2009;100:732–38CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Oki E, Baba H, Tokunaga E, et al. AKT phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. Int. J. Cancer. 2005:117;376–80CrossRefPubMedGoogle Scholar
  12. 12.
    Radu OM, Foxwell T, Cieply K, Navina S, Dacic S, Nason KS, Davison JM. HER2 amplification in gastroesophageal adenocarcinoma: correlation of two antibodies using gastric cancer scoring criteria, H score, and digital image analysis with fluorescence in situ hybridization. Am J Clin Pathol. 2012; 137:583–94.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337–45.CrossRefPubMedGoogle Scholar
  14. 14.
    Ando K, Kakeji Y, Kitao H, et al. High expression of BUBR1 is one of the factors for inducing DNA aneuploidy and progression in gastric cancer. Cancer Sci. 2010;101:639–45.CrossRefPubMedGoogle Scholar
  15. 15.
    Furuya T, Uchiyama T, Murakami T et al. Relationship between chromosomal instability and intratumoral regional DNA ploidy heterogeneity in primary gastric cancers. Clin Cancer Res. 2000;6:2815–20.PubMedGoogle Scholar
  16. 16.
    Seabright, M. (1971) A rapid banding technique for human chromosomes. Lancet. 1971;30:971–72.CrossRefGoogle Scholar
  17. 17.
    Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res. 2001;7:2958–70.PubMedGoogle Scholar
  18. 18.
    Galizia G, Lieto E, Ferraraccio F, et al. Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery. Ann Surg Oncol. 2006;13:823–35.CrossRefPubMedGoogle Scholar
  19. 19.
    Garcia I, Vizoso F, Martin A, Sanz L, Abdel-Lah O, Raigoso P, Garcia-Muniz JL. Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol. 2003;10:234–41.CrossRefPubMedGoogle Scholar
  20. 20.
    Galizia G, Lieto E, Orditura M, et al. Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World J Surg. 2007;31:1458–68.CrossRefPubMedGoogle Scholar
  21. 21.
    Fusco N, Elena GR, Claudia DC. HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions. Mod Pathol. 2013; 26:1–9.Google Scholar
  22. 22.
    Masanori T, Kitada K. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res. 2012;18:5992–6000.CrossRefGoogle Scholar
  23. 23.
    Berg D, Wolff C, Malinowsky K, et al. Profiling signalling pathways in formalin-fixed and paraffin-embedded breast cancer tissues reveals cross-talk between EGFR, HER2, HER3 and uPAR. J Cell Physiol. 2012;227:204–12.CrossRefPubMedGoogle Scholar
  24. 24.
    Almhanna K, Strosberg J, Malafa M. Targeting AKT protein kinase in gastric cancer. Anticancer Res. 2011;31:4387–92.PubMedGoogle Scholar
  25. 25.
    Hudis C, Swanton C, Janjigian YY, et al. A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors. Breast Cancer Res. 2013;19:R110. doi: 10.1186/bcr3577.CrossRefGoogle Scholar
  26. 26.
    Baba H, Korenaga D, Kakeji Y, Haraguchi M, Okamura T, Maehara Y. DNA ploidy and its clinical implications in gastric cancer. Surgery 2002;131:S63–70.CrossRefPubMedGoogle Scholar
  27. 27.
    Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res. 2006;12:5268–72.CrossRefPubMedGoogle Scholar
  28. 28.
    Zasadil LM, Britigan EM, Weaver BA. 2n or not 2n: Aneuploidy, polyploidy and chromosomal instability in primary and tumor cells. Semin Cell Dev Biol. 2013;24:370–9.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Araujo SE, Bernardo WM, Habr-Gama A, Kiss DR, Cecconello I. DNA ploidy status and prognosis in colorectal cancer: a meta-analysis of published data. Dis Colon Rectum. 2007;50:1800–10.CrossRefPubMedGoogle Scholar
  30. 30.
    Habermann JK, Brucker CA, Freitag-Wolf S, et al. Genomic instability and oncogene amplifications in colorectal adenomas predict recurrence and synchronous carcinoma. Mod Pathol. 2011;24:542–55.CrossRefPubMedGoogle Scholar
  31. 31.
    Ly P, Eskiocak U, Kim SB, et al. Characterization of aneuploid populations with trisomy 7 and 20 derived from diploid human colonic epithelial cells. Neoplasia. 2011;13:348–357.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Ly P, Kim SB, Kaisani AA, Marian G, Wright WE, Shay JW. Aneuploid human colonic epithelial cells are sensitive to AICAR-induced growth inhibition through EGFR degradation. Oncogene. 2013;32:3139–46.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Li L, Dutra A, Pak E, Labrie JE 3rd, et al. EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors. Neuro Oncol. 2009;11:9–21.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Mardin BR, Isokane M, Cosenza MR, Krämer A, Ellenberg J, Fry AM, Schiebel E. EGF-induced centrosome separation promotes mitotic progression and cell survival. Dev Cell. 2013;25:229–40.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Society of Surgical Oncology 2016

Authors and Affiliations

  • Yuichi Hisamatsu
    • 1
  • Eiji Oki
    • 1
  • Hajime Otsu
    • 1
  • Koji Ando
    • 1
  • Hiroshi Saeki
    • 1
  • Eriko Tokunaga
    • 1
  • Shinichi Aishima
    • 2
  • Masaru Morita
    • 1
  • Yoshinao Oda
    • 2
  • Yoshihiko Maehara
    • 1
  1. 1.Department of Surgery and Science, Graduate School of Medical SciencesKyushu UniversityFukuokaJapan
  2. 2.Department Anatomic Pathology and Pathological Sciences, Graduate School of Medical SciencesKyushu UniversityFukuokaJapan

Personalised recommendations